{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:06Z","timestamp":1793830446297,"version":"4.6.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009859","name":"Geoffrey Beene Cancer Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009859","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"Caring for the Carcinoid\/NETRF"},{"name":"NIH\/NCI Paul Calabresi Career Development Award for Clinical Oncology","award":["K12 CA184746"],"award-info":[{"award-number":["K12 CA184746"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00259-018-4193-y","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T09:22:16Z","timestamp":1540804936000},"page":"677-685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-4531","authenticated-orcid":false,"given":"Simone","family":"Krebs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Pandit-Taskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Reidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge K.","family":"Lyashchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"key":"4193_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","volume":"40","author":"B Lawrence","year":"2011","unstructured":"Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40:1\u201318 vii.","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"Suppl 2","key":"4193_CR2","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1093\/annonc\/12.suppl_2.S47","volume":"12","author":"GA Kaltsas","year":"2001","unstructured":"Kaltsas GA, Mukherjee JJ, Grossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann Oncol. 2001;12(Suppl 2):S47\u201350.","journal-title":"Ann Oncol"},{"key":"4193_CR3","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2967\/jnumed.112.114165","volume":"54","author":"RC Walker","year":"2013","unstructured":"Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013;54:855\u201360.","journal-title":"J Nucl Med"},{"key":"4193_CR4","doi-asserted-by":"publisher","first-page":"16436","DOI":"10.1073\/pnas.0607761103","volume":"103","author":"M Ginj","year":"2006","unstructured":"Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103:16436\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4193_CR5","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.2967\/jnumed.111.095778","volume":"52","author":"R Cescato","year":"2011","unstructured":"Cescato R, Waser B, Fani M, Reubi JC. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52:1886\u201390.","journal-title":"J Nucl Med"},{"key":"4193_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","volume":"55","author":"D Wild","year":"2014","unstructured":"Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248\u201352.","journal-title":"J Nucl Med"},{"key":"4193_CR7","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","volume":"53","author":"M Fani","year":"2012","unstructured":"Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53:1481\u20139.","journal-title":"J Nucl Med"},{"issue":"6","key":"4193_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2967\/jnumed.117.199737","volume":"59","author":"GP Nicolas","year":"2017","unstructured":"Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, et al. Safety, biodistribution, and radiation dosimetry of (68)Ga-OPS202 ((68)Ga-NODAGA-JR11) in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase I imaging study. J Nucl Med. 2017;59(6):909\u201314.","journal-title":"J Nucl Med"},{"key":"4193_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2967\/jnumed.117.199760","volume":"59","author":"GP Nicolas","year":"2018","unstructured":"Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, et al. Sensitivity comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59:915\u201321.","journal-title":"J Nucl Med"},{"key":"4193_CR10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","volume":"36","author":"F Forrer","year":"2009","unstructured":"Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4193_CR11","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med"},{"key":"4193_CR12","first-page":"1","volume":"37","author":"IRCP","year":"2007","unstructured":"IRCP. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37:1\u2013332.","journal-title":"Ann ICRP"},{"key":"4193_CR13","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2967\/jnumed.117.191684","volume":"58","author":"GP Nicolas","year":"2017","unstructured":"Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, et al. Biodistribution, pharmacokinetics, and dosimetry of (177)Lu-, (90)Y-, and (111)in-labeled somatostatin receptor antagonist OPS201 in comparison to the agonist (177)Lu-DOTATATE: the mass effect. J Nucl Med. 2017;58:1435\u201341.","journal-title":"J Nucl Med"},{"key":"4193_CR14","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2967\/jnumed.113.120600","volume":"54","author":"M Sandstrom","year":"2013","unstructured":"Sandstrom M, Velikyan I, Garske-Roman U, Sorensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54:1755\u20139.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-018-4193-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-4193-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-4193-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T20:15:08Z","timestamp":1572293708000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-018-4193-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["4193"],"URL":"https:\/\/doi.org\/10.1007\/s00259-018-4193-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"17 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DR was a member of the Advisory Board for Ipsen, Novartis, Advanced Accelerator Applications (AAA), and Lexicon Pharmaceuticals\u00a0and has received research funding from Ipsen and Novartis. LB acted as a consultant for Advanced Accelerator Applications (AAA) and Ipsen. WW\u00a0has served as\u00a0a consultant for Endocyte, Ipsen, and Piramal Imaging. JAD has served as a consultant to WILEX AG, Algeta\u00a0ASA, and Janssen Pharmaceuticals, Inc. SK, NP, BJB, SKL, and JSL declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed written consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}